Nasal spray vaccine aims to protect kids from two breathing viruses

NCT ID NCT06546423

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two experimental nasal spray vaccines in 24 children aged 2 to 5 years. The vaccines target two viruses that can cause breathing problems: human metapneumovirus (HMPV) and parainfluenza virus type 3 (HPIV3). The main goal was to see if the vaccines are safe and trigger an immune response. Children received a single dose of one of the two vaccines or a placebo, and were monitored for 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN METAPNEUMOVIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

parainfluenza virus type 3 infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CIR - Rangos, Johns Hopkins Bloomberg School of Public Health

    Baltimore, Maryland, 21205, United States

  • CIR South

    Columbia, Maryland, 21045, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States